Abstract:Multiple myeloma (MM) is an incurable B-cell malignancy. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission. Arsenic trioxide (As2O3) is an effective treatment for acute promyelocytic leukemia. Current clinical studies are investigating arsenic as a therapeutic agent for malignancies. The mechanism of cytotoxicity inducted by As2O3 has not been known thoroughly. Constitutively activated NF-κB is a characteristic of different tumor entities including MM clones and malignant plasma cells from MM patients. It plays an important role in maintaining tumor cell proliferation and protecting cell from apoptosis. The study was to explore the possible mechanism of As2O3 effects on MM lines. Materials and methods: The human MM cell lines of KM3 and RPMI8226 were provided by Hematology Institution of Zhejiang University. The concentration of As2O3 in cell culture system was from 0.5μmol/L to 20μmol/L, 24 hours was selected as the termination point of cell culture. Cell culture without As2O3 and first-antibody-dismissed test were enrolled as controls. Both of the MM lines were treated with As2O3 in various concentrations. The restrained proliferation was observed by drawing growth curve. MTT bioassay was used to examine the effect of As2O3 on cell growth and the concentration of 50% growth inhibition( IC50) calculated respectively. Apoptosis and changes of IκB-α protein was observed by flow cytometry(FCM). Changes and subcellular localization of IκB-α protein were observed by fluorescence microscopy. Western blot was also used to analyze the expression of NF-κB in nuclear. Results: As2O3 inhibited the proliferation of both MM lines, and IC50 of KM3 and RPMI8226 was 9.61μmol/L and 8.01μmol/L respectively. After exposure to As2O3, both of the lines were induced to apoptosis. With As2O3 concentration varied from 0.5μmol/L to 20μmol/L the apoptosis rate of KM3 and RPMI8226 was concentration-dependent measured by FCM. After 24 hours treated with 20μmol/L As2O3, the apoptosis rate of KM3 cells was 41.18% while that of RPMI8226 was 65.25%. It seemed that RPMI8226 cell was more sensitive to As2O3. FCM analysis showed a significant increase in the percentage of G2/M phase cells, from 13.74% to 41.72%, and a decrease percentage of S phase cells from 35.11% to 23.96%. The level of IκB-α in cytoplasm was down-regulated after As2O3 stimulation in both cell lines. The down-regulation of IκB-α from 79.68% to 51.57% was confirmed by FCM in KM3 treated with 10μmol/L As2O3 (p<0.01), the effect was concentration-dependent. While the IκB-α in RPMI8226 changed from 79.72% to 34.08% (p<0.01). Immunofluorescence assay showed that IκB-α localized in cytoplasm mostly. The level of IκB-α protein was down-regulated after As2O3 stimulation. The results showed that KM3 and RPMI8226 lines expressed constitutively activity NF-κB and As2O3 down-regulated the constitutive expression of NF-κB in both cell lines but with different kinetics. Conclusions: As2O3 could not only inhibit the proliferation but also induce apoptosis of KM3 and RPMI8226 cells. The mechanisms of its effect on MM cells may include decreasing the constitutive activity of NF-κB, subsequently down-regulating the expression of various gene products controlled by NF-κB, thus inducing apoptosis in MM cells. As2O3 could inhibit the proliferation of MM cells by changing MM cell cycle and inducing G2/M phase arrest.

Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines]

Mechanism Of Arsenic Trioxide-Induced Apoptosis On Multiple Myeloma Cells.

Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells

[Apoptosis in Jurkat Cells Induced by Bortezomib Combined with Adriamycin].

Apoptosis of RPMI8226 cell induced by arsenic trioxide combined with bortezomib and its mechanism

Arsenic trioxide and 2-methoxyestradiol reduce β-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib

[Inhibition Effect of Arsenic Trioxide on the Growth of Human MDS Cell Line MUTZ-1 Cells].

Arsenic Trioxide Induces Not Only Apoptosis but Also Autophagic Cell Death in Leukemia Cell Lines Via Up-Regulation of Beclin-1

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

[Study on the Relationship of Beta-Catenin Level and Sensitivity to Bortezomib of Myeloma Cell Lines].

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

The Study of Bortezomib Alone or in Combination with Harringtonine or Arsenic Trioxide on Proliferation and Apoptosis of Multidrug Resistant Leukemic Cells.

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

A Study on Interaction of Aspirin and Bortezomib in Multiple Myeloma Cells

[Caspase-Independent Apoptosis Induced by Arsenic Trioxide in Human Multiple Myeloma Cell RPMI8226].

Aspirin Enhances the Cytotoxic Activity of Bortezomib Against Myeloma Cells Via Suppression of Bcl-2, Survivin and Phosphorylation of AKT

A Study on the relationship of Autophagy and Apoptosis Induced by Arsenic Trioxide in Human Multiple Myeloma Cell RPMI 8226

Effects of bortezomib on growth inhibition of pancreatic cancer cells BxPC3 and SW1990 in vitro

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells]

Ascorbic acid enhances apoptosis of multiple myeloma RPMI 8226 cells induced by arsenic trioxide